Stockreport

Athenex Announces Positive Topline Results from Two Phase III Studies of KX2-391 Ointment 1% Featured in Late Breaker Program at the 2019 American Academy of Dermatology Annual Meeting

Athenex, Inc.  (ATNX) 
Last athenex, inc. earnings: 2/27 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.athenex.com
PDF Results show that 44% and 54% of patients in studies KX01-AK-003 and KX01-AK-004, respectively, achieved 100% AK lesion clearance at Day 57 Safety profile of KX2-391 oi [Read more]